AAPL338.11+1.11 (+0.33%) ▲|ABBV263.19-0.82 (-0.31%) ▼|ABT102.26+0.03 (+0.03%) ▲|ACN185.30-4.98 (-2.62%) ▼|ADBE249.24-3.43 (-1.36%) ▼|AMAT428.38+10.98 (+2.63%) ▲|AMD547.76+2.67 (+0.49%) ▲|AMGN382.29+2.51 (+0.66%) ▲|AMT174.00-1.62 (-0.92%) ▼|AMZN252.53+1.34 (+0.53%) ▲|AVGO360.56+13.26 (+3.82%) ▲|AXP309.73-1.75 (-0.56%) ▼|BA197.61+0.55 (+0.28%) ▲|BAC57.79-0.38 (-0.65%) ▼|BKNG169.71-0.81 (-0.48%) ▼|BLK1,047.92-5.84 (-0.55%) ▼|BMY62.43-0.41 (-0.64%) ▼|BNY152.74-0.30 (-0.19%) ▼|BRK-B507.43-1.68 (-0.33%) ▼|C132.18-0.52 (-0.39%) ▼|CAT808.88+10.43 (+1.31%) ▲|CL87.26-0.47 (-0.54%) ▼|CMCSA22.58-0.34 (-1.46%) ▼|COF201.89-0.10 (-0.05%) ▼|COP133.10-0.11 (-0.08%) ▼|COST894.23+0.30 (+0.03%) ▲|CRM240.73-2.31 (-0.95%) ▼|CSCO110.43+0.19 (+0.18%) ▲|CVS88.98-1.29 (-1.43%) ▼|CVX211.72+0.13 (+0.06%) ▲|DE685.41-0.20 (-0.03%) ▼|DHR212.02-0.49 (-0.23%) ▼|DIS103.56-1.78 (-1.69%) ▼|DUK117.40-1.16 (-0.98%) ▼|EMR148.09+0.70 (+0.47%) ▲|FDX304.81-1.09 (-0.35%) ▼|GD355.30-0.63 (-0.18%) ▼|GE311.50-2.11 (-0.67%) ▼|GEV946.50+21.15 (+2.29%) ▲|GILD151.48+0.59 (+0.39%) ▲|GM84.95-1.65 (-1.91%) ▼|GOOG351.70+8.02 (+2.33%) ▲|GOOGL355.65+8.32 (+2.40%) ▲|GS946.13-4.99 (-0.52%) ▼|HD298.82-3.70 (-1.22%) ▼|HON205.94-0.55 (-0.27%) ▼|IBM233.44-4.37 (-1.84%) ▼|INTC109.72+0.92 (+0.85%) ▲|INTU306.83-6.31 (-2.01%) ▼|ISRG393.49+9.95 (+2.59%) ▲|JNJ268.02-2.20 (-0.81%) ▼|JPM346.15-3.10 (-0.89%) ▼|KO87.87-0.20 (-0.22%) ▼|LIN455.21-3.28 (-0.71%) ▼|LLY1,150.60-1.72 (-0.15%) ▼|LMT535.00-2.96 (-0.55%) ▼|LOW192.76-1.37 (-0.70%) ▼|LRCX279.23+9.92 (+3.68%) ▲|MA564.08-1.68 (-0.30%) ▼|MCD248.09-0.39 (-0.16%) ▼|MDLZ60.80-1.25 (-2.01%) ▼|MDT92.40-0.41 (-0.44%) ▼|META672.81-9.51 (-1.39%) ▼|MMM164.09-0.64 (-0.39%) ▼|MO69.27-0.43 (-0.62%) ▼|MRK146.53-0.60 (-0.41%) ▼|MS202.12-1.36 (-0.67%) ▼|MSFT493.74-4.01 (-0.81%) ▼|MU990.46+12.96 (+1.33%) ▲|NEE80.64-0.62 (-0.76%) ▼|NFLX71.37-3.94 (-5.23%) ▼|NKE36.22-0.17 (-0.46%) ▼|NOW137.07-1.43 (-1.03%) ▼|NVDA219.73+0.39 (+0.18%) ▲|ORCL146.68-3.90 (-2.59%) ▼|PEP130.19-3.47 (-2.60%) ▼|PFE27.45-0.19 (-0.69%) ▼|PG146.33-1.18 (-0.80%) ▼|PLTR172.84-3.40 (-1.93%) ▼|PM188.19-2.33 (-1.22%) ▼|QCOM187.44-1.27 (-0.67%) ▼|RTX192.73-0.81 (-0.42%) ▼|SBUX95.45-1.22 (-1.26%) ▼|SCHW104.80+0.17 (+0.16%) ▲|SO85.91-0.85 (-0.98%) ▼|SPG203.48-0.99 (-0.48%) ▼|T25.35-0.04 (-0.16%) ▼|TMO657.36-1.34 (-0.20%) ▼|TMUS165.60-0.85 (-0.51%) ▼|TSLA369.71+3.51 (+0.96%) ▲|TXN261.94+3.80 (+1.47%) ▲|UBER70.36-0.51 (-0.72%) ▼|UNH374.12-1.09 (-0.29%) ▼|UNP279.19-3.30 (-1.17%) ▼|UPS99.33-0.84 (-0.84%) ▼|USB59.97-0.29 (-0.47%) ▼|V368.04-1.89 (-0.51%) ▼|VZ47.71-0.63 (-1.29%) ▼|WFC86.27-0.62 (-0.71%) ▼|WMT107.63+0.84 (+0.79%) ▲|XOM162.59-0.68 (-0.42%) ▼|AAPL338.11+1.11 (+0.33%) ▲|ABBV263.19-0.82 (-0.31%) ▼|ABT102.26+0.03 (+0.03%) ▲|ACN185.30-4.98 (-2.62%) ▼|ADBE249.24-3.43 (-1.36%) ▼|AMAT428.38+10.98 (+2.63%) ▲|AMD547.76+2.67 (+0.49%) ▲|AMGN382.29+2.51 (+0.66%) ▲|AMT174.00-1.62 (-0.92%) ▼|AMZN252.53+1.34 (+0.53%) ▲|AVGO360.56+13.26 (+3.82%) ▲|AXP309.73-1.75 (-0.56%) ▼|BA197.61+0.55 (+0.28%) ▲|BAC57.79-0.38 (-0.65%) ▼|BKNG169.71-0.81 (-0.48%) ▼|BLK1,047.92-5.84 (-0.55%) ▼|BMY62.43-0.41 (-0.64%) ▼|BNY152.74-0.30 (-0.19%) ▼|BRK-B507.43-1.68 (-0.33%) ▼|C132.18-0.52 (-0.39%) ▼|CAT808.88+10.43 (+1.31%) ▲|CL87.26-0.47 (-0.54%) ▼|CMCSA22.58-0.34 (-1.46%) ▼|COF201.89-0.10 (-0.05%) ▼|COP133.10-0.11 (-0.08%) ▼|COST894.23+0.30 (+0.03%) ▲|CRM240.73-2.31 (-0.95%) ▼|CSCO110.43+0.19 (+0.18%) ▲|CVS88.98-1.29 (-1.43%) ▼|CVX211.72+0.13 (+0.06%) ▲|DE685.41-0.20 (-0.03%) ▼|DHR212.02-0.49 (-0.23%) ▼|DIS103.56-1.78 (-1.69%) ▼|DUK117.40-1.16 (-0.98%) ▼|EMR148.09+0.70 (+0.47%) ▲|FDX304.81-1.09 (-0.35%) ▼|GD355.30-0.63 (-0.18%) ▼|GE311.50-2.11 (-0.67%) ▼|GEV946.50+21.15 (+2.29%) ▲|GILD151.48+0.59 (+0.39%) ▲|GM84.95-1.65 (-1.91%) ▼|GOOG351.70+8.02 (+2.33%) ▲|GOOGL355.65+8.32 (+2.40%) ▲|GS946.13-4.99 (-0.52%) ▼|HD298.82-3.70 (-1.22%) ▼|HON205.94-0.55 (-0.27%) ▼|IBM233.44-4.37 (-1.84%) ▼|INTC109.72+0.92 (+0.85%) ▲|INTU306.83-6.31 (-2.01%) ▼|ISRG393.49+9.95 (+2.59%) ▲|JNJ268.02-2.20 (-0.81%) ▼|JPM346.15-3.10 (-0.89%) ▼|KO87.87-0.20 (-0.22%) ▼|LIN455.21-3.28 (-0.71%) ▼|LLY1,150.60-1.72 (-0.15%) ▼|LMT535.00-2.96 (-0.55%) ▼|LOW192.76-1.37 (-0.70%) ▼|LRCX279.23+9.92 (+3.68%) ▲|MA564.08-1.68 (-0.30%) ▼|MCD248.09-0.39 (-0.16%) ▼|MDLZ60.80-1.25 (-2.01%) ▼|MDT92.40-0.41 (-0.44%) ▼|META672.81-9.51 (-1.39%) ▼|MMM164.09-0.64 (-0.39%) ▼|MO69.27-0.43 (-0.62%) ▼|MRK146.53-0.60 (-0.41%) ▼|MS202.12-1.36 (-0.67%) ▼|MSFT493.74-4.01 (-0.81%) ▼|MU990.46+12.96 (+1.33%) ▲|NEE80.64-0.62 (-0.76%) ▼|NFLX71.37-3.94 (-5.23%) ▼|NKE36.22-0.17 (-0.46%) ▼|NOW137.07-1.43 (-1.03%) ▼|NVDA219.73+0.39 (+0.18%) ▲|ORCL146.68-3.90 (-2.59%) ▼|PEP130.19-3.47 (-2.60%) ▼|PFE27.45-0.19 (-0.69%) ▼|PG146.33-1.18 (-0.80%) ▼|PLTR172.84-3.40 (-1.93%) ▼|PM188.19-2.33 (-1.22%) ▼|QCOM187.44-1.27 (-0.67%) ▼|RTX192.73-0.81 (-0.42%) ▼|SBUX95.45-1.22 (-1.26%) ▼|SCHW104.80+0.17 (+0.16%) ▲|SO85.91-0.85 (-0.98%) ▼|SPG203.48-0.99 (-0.48%) ▼|T25.35-0.04 (-0.16%) ▼|TMO657.36-1.34 (-0.20%) ▼|TMUS165.60-0.85 (-0.51%) ▼|TSLA369.71+3.51 (+0.96%) ▲|TXN261.94+3.80 (+1.47%) ▲|UBER70.36-0.51 (-0.72%) ▼|UNH374.12-1.09 (-0.29%) ▼|UNP279.19-3.30 (-1.17%) ▼|UPS99.33-0.84 (-0.84%) ▼|USB59.97-0.29 (-0.47%) ▼|V368.04-1.89 (-0.51%) ▼|VZ47.71-0.63 (-1.29%) ▼|WFC86.27-0.62 (-0.71%) ▼|WMT107.63+0.84 (+0.79%) ▲|XOM162.59-0.68 (-0.42%) ▼|
23.5 C
New York
Friday, September 18, 2026

Tag: management

newssourceFORcompanyinformationcontent1releasesmarket

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival.

SAMBAZON® Launches New Pre-Topped Açaí & Smoothie Bowls for Ultimate Convenience

SAN CLEMENTE, Calif., June 2, 2025 /PRNewswire/ -- SAMBAZON®, the leader of Certified Organic and Fair Trade Açaí products, is excited to announce the launch...

Cancer Pain Market Set to Transform by 2034 Due to Launch of Breakthrough Therapies | DelveInsight

According to DelveInsight's analysis, the growth of the cancer pain market is expected to be mainly driven by increasing incidence and advances in disease...

The Inner Circle acknowledges, Kalie J. Swain as a Pinnacle Professional Member

BRYAN, Texas, June 12, 2025 /PRNewswire/ -- Prominently featured in The Inner Circle, Kalie J. Swain is acknowledged as a Pinnacle Professional Member Inner...

Youth Serving Nonprofits Showcase Community Impact through Baltimore Children & Youth Fund’s 2025 Community Exhibition

BALTIMORE, June 12, 2025 /PRNewswire/ -- On June 3, over 250 community members, leaders, and mentors gathered at Baltimore Unity Hall for the Baltimore Children...

Hapbee Is Upgrading U.S. Listing to OTCID to Expand Investor Access and Increase Market Visibility

Hapbee Also Updates Status of Audited Financial Statements 
Hapbee Also Updates Status of Audited Financial Statements

RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit

SAN DIEGO, June 12, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT)...

DraftKings to Introduce Transaction Fee in Illinois

BOSTON, June 12, 2025 (GLOBE NEWSWIRE) -- In response to the recent and prior sports wagering tax increases passed by the Illinois state legislature on all mobile and online sports wagers placed with licensed operators, DraftKings Inc. (Nasdaq: DKNG) today announced that it will implement a 50-cent transaction fee on all mobile and online bets placed in Illinois through DraftKings Sportsbook, effective September 1, 2025.

Coherent Introduces Breakthrough Diamond-Silicon Carbide Material for Next Generation Thermal Management in AI and High-Performance Computing

BREAKTHROUGH DIAMOND-SILICON CARBIDE MATERIAL FOR NEXT GENERATION THERMAL MANAGEMENT IN AI AND HIGH- PERFORMANCE COMPUTING

Equifax Secures 35 New Patents, Advancing Responsible AI, Machine Learning, and Fraud & Identity Solutions

New Patents Secured in the First Half of 2025 Help Drive Responsible AI Innovation and Create More Effective Insights for Customers ATLANTA, June 12, 2025...

Ryman Hospitality Properties, Inc. Announces Second Quarter 2025 Earnings Conference Call – Tuesday, August 5, 2025, 10 a.m. ET

NASHVILLE, Tenn., June 12, 2025 (GLOBE NEWSWIRE) -- Ryman Hospitality Properties, Inc. (NYSE: RHP) (the "Company”), a leading lodging and hospitality real estate investment trust that specializes in upscale convention center resorts and entertainment experiences, announced today that it will release its second quarter 2025 earnings results after the market closes on Monday, August 4, 2025. Management will hold a conference call to discuss the quarter's results at 10 a.m. ET on Tuesday, August 5, 2025.

Carrier Board of Directors Declares Quarterly Cash Dividend

PALM BEACH GARDENS, Fla., June 12, 2025 /PRNewswire/ -- Carrier Global Corporation (NYSE: CARR), global leader in intelligent climate and energy solutions, announced today...

New York Mortgage Trust Declares Second Quarter 2025 Common Stock Dividend of $0.20 Per Share, and Preferred Stock Dividends

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- New York Mortgage Trust, Inc. (Nasdaq: NYMT) (the “Company”) announced today that its Board of Directors (the “Board”) declared a regular quarterly cash dividend of $0.20 per share on shares of its common stock for the quarter ending June 30, 2025. The dividend will be payable on July 30, 2025 to common stockholders of record as of the close of business on June 23, 2025.

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsManagement

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers